On September 8, 2022 Servier reported The ESMO (Free ESMO Whitepaper) (European Society for Medical Oncology) 2022 Congress is taking place from September 9 to 13 in Paris and brings together more than 25,000 oncology professionals from over 160 countries around the world (Press release, Servier, SEP 8, 2022, View Source [SID1234619264]). This is an opportunity for Servier to present its R&D pipeline and new study data in the field of gastrointestinal cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

No less than 40 oncology projects are currently under development at Servier, focused on difficult-to-treat cancers, for targeted populations, and which respond to a high unmet medical need among patients.

In the field of solid tumors, Servier is developing treatments that target gastrointestinal cancers – Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Cholangiocarcinoma (a rare and aggressive bile-duct cancer) – and low-grade glioma (brain tumor). In hematology, the Group is continuing its research into certain types of leukemia, such as Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Lymphoma.

Claude Bertrand, Executive Vice President Research and Development of the Servier Group, said: "ESMO is a major international congress where we can share and discuss our latest scientific and medical advances in oncology with the scientific community. Five years after making our strategic commitment to the fight against cancer, this conference allows us to highlight the progress made by the Group, our teams, and our partners in developing therapeutic solutions to treat patients with hard-to-treat cancers."

Servier’s oncology R&D programs focus on two approaches: Immuno-Oncology, which aims to mobilize the immune system against cancer cells, and targeted therapies, which use precision medicine.

On September 8, 2022 SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS’’ or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, reported that reminds the investment community that it will host a virtual investor symposium on its lead asset, galinpepimut-S (GPS), including the potential commercial opportunity for GPS in AML patients (Press release, Sellas Life Sciences, SEP 8, 2022, View Source [SID1234619263]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call and webcast will be held on Thursday, September 15, 2022, from 1:00 p.m. to 2:00 p.m. ET featuring remarks from Angelos Stergiou, M.D., Sc.D. h.c., President and Chief Executive Officer, and Robert Francomano, Chief Commercial Officer.

For interested individuals unable to join the conference call, a replay will be available through September 29, 2022, at +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 13730135. An archived version of the webcast will also be available on SELLAS’ Investor Relations site: View Source

On September 8, 2022 Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, reported that it is scheduled to speak at the Morgan Stanley 20th Annual Global Healthcare Conference (Press release, Quest Diagnostics, SEP 8, 2022, View Source [SID1234619262]). Jim Davis, CEO-elect, and Sam Samad, Executive Vice President & CFO, will discuss the company’s vision, goals, and capital deployment strategies . The presentation is scheduled for Tuesday, September 13, 2022, at 4:40 p.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation and Q&A session will be webcast live during the conference and will be available on the company’s investor relations page which can be accessed at ir.QuestDiagnostics.com. In addition, the archived webcast will be available within 24 hours after the conclusion of the live event and will remain available until October 13, 2022.

On September 8, 2022 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, reported that Daphne Zohar, Founder and Chief Executive Officer, and Julie Krop, M.D., Chief Medical Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York City on Wednesday, September 14, 2022, at 2:05pm EDT (Press release, PureTech Health, SEP 8, 2022, View Source [SID1234619261]). A webcast of the presentation will be available at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 8, 2022 Propella Therapeutics, Inc. ("Propella" or "the Company"), a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, reported that Dr. Jose Avitia of the New Mexico Cancer Center will present data from the Company’s ongoing Phase 1/2 trial of PRL-02 for the treatment of advanced prostate cancer on Sunday, September 11 at 12:00 pm at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2022 (Press release, Propella Therapeutics, SEP 8, 2022, View Source [SID1234619260]). Details of the poster presentation are below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract: 2264
Title: 1/2a study of PRL-02, a long-acting IM depot injection of abiraterone decanoate in patients with prostate cancer (NCT04729114)
Presenter: Jose Avitia, M.D.
Date: September 11, 2022
Time: 12 pm CEST, Location: Hall 4, Paris Expo Porte de Versailles, Paris, France
Presentation Number: 1386P

The presentation will highlight results from the ongoing dose-escalation part of the Phase 1/2 study (NCT04729114) in 15 patients who have been treated at five different doses of PRL-02 (180mg; 360mg; 720mg; 1260mg; 1800mg), including safety, tolerability and response data.

Propella Therapeutics is focused on the creation of a pipeline of proprietary oncology therapeutics that utilize lymphatic system delivery. The Company’s most advanced clinical candidate, PRL-02 (abiraterone decanoate), is a long-acting, selective CYP17 lyase inhibitor that has been designed for optimal uptake through the lymphatic system so that a precise level of abiraterone can be released to continuously block CYP17 lyase over a three-month period, thereby reducing the risk of tumor breakthrough. PRL-02 is currently in an open-label, multi-center Phase 1/2 study for the treatment of metastatic prostate cancer.

About Metastatic Prostate Cancer

Prostate cancer is the most common non-skin cancer in men, and the second leading cause of cancer death, developing most often in older men. Metastatic disease occurs when prostate cancer cells travel through the lymphatic system or blood stream to other organs and tissues such as lymph nodes, liver, bone, and lungs. While early or localized prostate cancer remains highly curable, advanced prostate cancer remains difficult to treat, with a 5-year survival rate of only 30%. Although there are several treatment options for metastatic prostate cancer, the reduction of androgen activity remains the most effective approach.

About PRL-02

PRL-02 is a next generation androgen biosynthesis inhibitor being developed for the treatment of prostate cancer. A large body of both historic and modern data support a role for androgens in prostate cancer pathogenesis and progression. The only approved androgen biosynthesis inhibitor approved for the treatment of prostate cancer, Zytiga (oral abiraterone acetate), blocks the CYP17 lyase enzyme that is required for the biosynthesis of androgens, including testosterone, but also unnecessarily blocks the CYP17 hydroxylase enzyme activity, resulting in a large accumulation of mineralocorticoids that can produce a constellation of side effects (hypertension, hypokalemia, edema) and upstream steroids such as progesterone that can further stimulate prostate cancer growth. PRL-02 is a patented prodrug of abiraterone designed for lymphatic targeting of tissues and tumors that express the CYP17 lyase enzyme. PRL-02 is an intramuscular depot that, when given along with a gonadotropin releasing hormone agonist or antagonist, was engineered to precisely release the abiraterone needed to continuously block CYP17 lyase enzyme for 3 months, while avoiding adverse liver and drug-drug interaction effects and the accumulation of steroids that can further stimulate prostate cancer and produce the symptoms of mineralocorticoid excess that arise from unwanted CYP17 hydroxylase inhibition.